January 2023 EditionJanuary 3, 2023
Updated Diabetes Practice Guidelines
The American Diabetes Association (ADA) has released the “Standards of Care in Diabetes – 2023,” which provides vital new and updated practice guidelines to care for people with diabetes and prediabetes. Read the ADA’s press release here for notable updates and changes.
Clinical Alerts: Drug Shortages
The U.S. is experiencing shortages of oseltamivir (Tamiflu), albuterol, and oral amoxicillin and amoxicillin clavulanate (Augmentin). Get the details in these Clinical Alerts:
Embed QAPI in the Culture to Combat Staffing Challenges
CMS now requires Quality Assurance and Performance Improvement (QAPI) programs to deal with a full range of facility processes, from resident billing to abuse reporting. This will require a complete culture change that calls for input from everyone. Learn how to build staff involvement and loyalty through QAPI.
E-Guide: Medication Management – Reducing Risk and Improving Outcomes for Individuals with I/DD
Individuals with I/DD tend to have more comorbidities and take more long-term medications than the general population. Given the risks for polypharmacy and adverse effects, effective medication management is key to achieving healthier outcomes. Learn 3 tips for successful medication management in this population.
KRAZATI™ Receives FDA Approval for Treatment of Non-Small Cell Lung Cancer
KRAZATI™ (adagrasib) was recently approved by the FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy.
Amerita Published Study Shows Importance of Home Parenteral Nutrition
A recent study by Amerita, published in BMJ Nutrition, Prevention & Health, shows the importance of home parenteral nutrition (HPN) and a multidisciplinary nutritional support team for patients with intestinal failure requiring long-term nutritional support.
Drug Pricing Reform in the Inflation Reduction Act
The Inflation Reduction Act, signed by President Biden in August 2022, will have far-reaching effects and important consequences for the nation’s drug pricing system. This article, the first in a 2-part series from the Duke-Margolis Center for Health Policy at Duke University, sums up some of the expected impacts.
All webinar times are 1:00pm ET / 12:00pm CT
Tuesday, January 10: The Four Ds of Narcotics
Tuesday, January 17: Steps to Fall Prevention
Tuesday, January 31: Psychotropic Stewardship: Practical Solutions to Impractical Challenges
Tuesday, February 7: Developing a Strategic Approach for IV Therapy
Tuesday, February 14: PEDs and the Medication Mix in Assisted Living
Tuesday, March 7: Insulin Management